ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Ravandi on Resistance in AML

Farhad Ravandi, MD
Published: Tuesday, Mar 04, 2014

Farhad Ravandi, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses resistance in adults with acute myeloid leukemia (AML).

Ravandi says resistance in AML is not well defined. A study that attempted to find a mechanism of predicting resistance in adults with AML combined data from multiple centers and cooperative groups. Unfortunately, Ravandi says, the study showed that there is no clear way of predicting resistance.

Ravandi believes that one of the biggest issues of resistance in AML is that wide ranges of drug doses are used and patients are particularly heterogeneous. In the future, leukemia and AML should be treated based on disease in order to combat resistance to therapies, Ravandi says.

Farhad Ravandi, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses resistance in adults with acute myeloid leukemia (AML).

Ravandi says resistance in AML is not well defined. A study that attempted to find a mechanism of predicting resistance in adults with AML combined data from multiple centers and cooperative groups. Unfortunately, Ravandi says, the study showed that there is no clear way of predicting resistance.

Ravandi believes that one of the biggest issues of resistance in AML is that wide ranges of drug doses are used and patients are particularly heterogeneous. In the future, leukemia and AML should be treated based on disease in order to combat resistance to therapies, Ravandi says.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x